NRXP - long - catalyst play

٥ مارس

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

This is not a financial advice!

Upcoming catalysts 03/31/2024 and 06/30/2024

Today Rel. Vol. of 12.66

We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.

Keep an eye on 1.0, 1.5 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.

SL under 0.5

TPs approx. 2.20

Most info on the chart.

Trade carefully!

١٣ مارس

أغلقت الصفقة: تم الوصول لوقف الخسارة